Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
MRI-based Tumor Diganosis and Prognosis by Contrast Agents
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
A non-invasive MRI-based method to diagnose breast cancer using specific binding MRI contrast agents.. Breast cancer is the second most commonly diagnosed cancer among U.S. women, with a 13% incidence. The use of screening tests for early detection of......
Contact Avital Levy-lior
Participants
You
Email me a copy of this message

A non-invasive MRI-based method to diagnose breast cancer using specific binding MRI contrast agents.. Breast cancer is the second most commonly diagnosed cancer among U.S. women, with a 13% incidence. The use of screening tests for early detection of breast cancer and other cancers provides better opportunities for patients to survive these cancers, with fewer side effects. Estrogen receptor (ER) is a well-established marker of breast cancer, and therefore the capacity to map this receptor may indicate high risk for cancer development. Current clinical methods that measure ER are subjective and semi-quantitative, or suffer from low target to non-target tissue image contrast. Hence, an accurate, standardized in vivo method to determine ER level would highly improve patient’s care. The present invention allows for the identification of ER by specific MRI contrast agents.


Applications


• Molecular imaging of the human breast for diagnostic and prognostic purposes


• Use in other steroid receptors that are implicated in breast cancer (progesterone) and other cancers (androgens in prostate cancer)


Advantages


• Non invasive • Non toxic


• Specific detection, diagnosis and prognosis evaluation of cancers


• Sufficiently potent both as a ligand of ER and a sensitive MRI contrast agent


• MRI of the receptors both in vitro and in vivo


Technology's Essence


Cancers such as breast and prostate cancer most frequently express the steroid receptors of their origin and can accumulate molecules that have high binding affinities for the receptors, namely, receptor ligands. In the outlined technology, new MRI sensitive ligands that bind specifically to the estrogen receptor were synthesized, in order to identify the presence of the receptors by non invasive MRI methods. These probes can map the estrogen receptor in vivo using contrast enhanced MRI.


Licensing Status

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2016
Technology Type DIAGNOSTIC
Phase of Development EARLY STAGE
CORPORATION